Terns Pharmaceuticals (TERN) Retained Earnings (2020 - 2023)
Historic Retained Earnings for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to -$311.6 million.
- Terns Pharmaceuticals' Retained Earnings fell 3751.74% to -$311.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$311.6 million, marking a year-over-year decrease of 3751.74%. This contributed to the annual value of -$242.4 million for FY2022, which is 3314.33% down from last year.
- Terns Pharmaceuticals' Retained Earnings amounted to -$311.6 million in Q3 2023, which was down 3751.74% from -$281.8 million recorded in Q2 2023.
- In the past 5 years, Terns Pharmaceuticals' Retained Earnings registered a high of -$131.9 million during Q4 2020, and its lowest value of -$311.6 million during Q3 2023.
- Moreover, its 4-year median value for Retained Earnings was -$202.8 million (2022), whereas its average is -$209.6 million.
- As far as peak fluctuations go, Terns Pharmaceuticals' Retained Earnings tumbled by 3802.3% in 2021, and later crashed by 3314.33% in 2022.
- Terns Pharmaceuticals' Retained Earnings (Quarter) stood at -$131.9 million in 2020, then tumbled by 38.02% to -$182.1 million in 2021, then crashed by 33.14% to -$242.4 million in 2022, then decreased by 28.54% to -$311.6 million in 2023.
- Its Retained Earnings stands at -$311.6 million for Q3 2023, versus -$281.8 million for Q2 2023 and -$263.9 million for Q1 2023.